CÁNCER DE MAMA
Pfizer (United States)
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Pfizer (United States) (4)
2021
2020
-
MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
Journal of Clinical Oncology, Vol. 38, Núm. 32, pp. 3753-3762
2007
-
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
Lancet, Vol. 369, Núm. 9561, pp. 559-570
2004
-
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
New England Journal of Medicine, Vol. 350, Núm. 11, pp. 1081-1092